A month after BTG (BTG) announced the US Food and Drug Association had granted clearance for its EKOS arterial/pulmonary ultrasonic technology, there was more good news for shareholders. The specialist healthcare group revealed revenues for its March year-end are now expected at or above the upper end of the guidance range of between £535m and £565m.
Sales were on the rise across the business units, save for the early-stage interventional pulmonary business. This took a hit from a reduction in procedures in Germany, its largest market. However, sales of varicose vein treatment Varithena increased over the year in response to marketing initiatives. Meanwhile, the interventional oncology business registered strong top-line growth, largely as a consequence of the continued rollout of its TheraSphere radiotherapy treatment in the US and Europe.